drugset / Trial / NCT01479595

A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

NCT01479595

Phase 2 Completed 65 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to investigate the efficacy and safety of QBX258 in subjects with moderate to severe asthma.

Timeline

Start
2012-02
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject QAX576 Monoclonal antibody 6 mg/kg Intravenous
Subject VAK694 Unknown 3 mg/kg Intravenous

Indications